Biocardia, Inc.
We are developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics. Our Pipeline: Our lead therapeutic candidate is FDA designated `Breakthrough` investigational CardiAMP™ Cell Therapy, which provides an autologous bone marrow derived cell therapy (using a patient`s own cells) for the treatment of two clinical indications - ischemic heart failure (BCDA-01) and chronic myocardial ischemia (BCDA-02). The Company’s second therapeutic platform, its NK1R+ MSC platform, an allogenic NK1 receptor positive mesenchymal stem cell population, an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of heart failure patients (BCDA-03) and acute respiratory distress syndrome (BCDA-04).
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Internationally (various countries)
About Us
Biocardia Takes a New and Comprehensive Approach to Heart Failure
We are developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases to improve the lives of patients from unmet medical needs.